BIOCRYST PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period
BIOCRYST PHARMACEUTICALS, INC. (BCRX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period of 717.00 thousand shares for the 12-month period ending 2016-12-31, per its 10-K filed 2017-02-27.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod · last filed 2017-02-27
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2015-12-31 was 5.00K shares.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2015-09-30 was 0.00 shares.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2015-06-30 was 0.00 shares.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2015-03-31 was 28.00K shares.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2016 was 717.00K shares, a 2072.73% increase from fiscal 2015.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2015 was 33.00K shares, a 62.50% decline from fiscal 2014.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2014 was 88.00K shares, a 95.11% decline from fiscal 2013.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2013 was 1.80M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 12 month as first filed |
|---|---|---|---|---|---|
| 2016-12-31 | 717.00K shares 10-K · filed 2017-02-27 | ||||
| 2015-12-31 | 5.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | 5.00K shares derived: sum of 2 quarters · filed 2017-02-27 | 5.00K shares derived: sum of 3 quarters · filed 2017-02-27 | 33.00K shares 10-K · filed 2017-02-27 | |
| 2015-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-06 | 0.00 shares derived: sum of 2 quarters · filed 2015-11-06 | 28.00K shares 10-Q · filed 2015-11-06 | 28.00K shares derived: sum of 4 quarters · filed 2017-02-27 | |
| 2015-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | 28.00K shares 10-Q · filed 2015-08-07 | 28.00K shares derived: sum of 3 quarters · filed 2017-02-27 | 28.00K shares derived: sum of 4 quarters · filed 2017-02-27 | |
| 2015-03-31 | 28.00K shares 10-Q · filed 2015-05-08 | 28.00K shares derived: sum of 2 quarters · filed 2017-02-27 | 28.00K shares derived: sum of 3 quarters · filed 2017-02-27 | ||
| 2014-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | 0.00 shares derived: sum of 2 quarters · filed 2017-02-27 | 88.00K shares 10-K · filed 2017-02-27 | -88.00K shares 10-K · filed 2015-03-02 | |
| 2014-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | 88.00K shares 10-Q · filed 2014-11-07 | |||
| 2014-06-30 | 88.00K shares 10-Q · filed 2014-08-08 | ||||
| 2013-12-31 | 1.80M shares 10-K · filed 2016-02-26 | -1.80M shares 10-K · filed 2015-03-02 | |||
| 2012-12-31 | -1.05M shares 10-K · filed 2015-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |